View Older Stories

May 5, 2026 04:05PM Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 28, 2026 09:05AM Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Apr 16, 2026 04:05PM Protagonist Therapeutics Reports Granting of Inducement Awards

Apr 14, 2026 03:13PM Jefferies stays Buy on Protagonist Therapeutics (PTGX) amid JNJ's bullish tone on Icotyde

Apr 14, 2026 01:03PM Protagonist Therapeutics (PTGX) PT Raised to $121 at Truist Securities

Apr 6, 2026 04:06PM Protagonist Therapeutics (PTGX) PT Raised to $116 at Clear Street

Mar 28, 2026 10:05AM Protagonist presents one-year ICOTYDE psoriasis data at AAD meeting

Mar 28, 2026 10:05AM Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 18, 2026 03:39PM Protagonist Therapeutics (PTGX) PT Raised to $104 at Clear Street

Mar 18, 2026 12:17PM Protagonist Therapeutics (PTGX) PT Raised to $119 at Barclays following Icotyde approval

Mar 18, 2026 12:14PM Protagonist Therapeutics (PTGX) PT Raised to $121 at Jefferies

Mar 18, 2026 10:28AM Truist Securities models $730M peak revenue for Protagonist Therapeutics (PTGX) in Icotyde royalties

Mar 18, 2026 08:05AM Protagonist receives FDA approval for psoriasis drug ICOTYDE

Mar 18, 2026 08:05AM Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

Mar 2, 2026 06:47AM Protagonist Therapeutics (PTGX) PT Raised to $100 at Wedbush

Mar 2, 2026 06:01AM FDA accepts rusfertide application with priority review for blood disorder

Feb 26, 2026 04:51AM Protagonist Therapeutics (PTGX) PT Raised to $112 at Citizens: 2 Approvals This Year

Feb 25, 2026 05:15PM CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 25, 2026 04:05PM Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jan 30, 2026 06:47AM Protagonist Therapeutics (PTGX) PT Raised to $117 at H.C. Wainwright

Jan 27, 2026 06:52AM JPMorgan on Protagonist Therapeutics (PTGX): 'The Kids Are Almost Out of the House'

Jan 5, 2026 09:38AM Protagonist Therapeutics (PTGX) PT Raised at Truist Ahead of 'Pivotal Year'

Jan 5, 2026 07:03AM Takeda and Protagonist submit drug application for polycythemia vera treatment

Dec 12, 2025 04:54AM Protagonist's (PTGX) Economics Can Change After Takeda Opt-out - Citizens

Dec 8, 2025 02:54AM Protagonist and Takeda report 52-week rusfertide data in polycythemia vera

Nov 20, 2025 04:00AM Jefferies Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Nov 7, 2025 05:04AM Protagonist Therapeutics (PTGX) PT Raised to $91 at Clear Street

Nov 6, 2025 06:42PM Protagonist Therapeutics (PTGX) Tops Q3 EPS by 1c

Nov 6, 2025 04:05PM Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025 09:26AM Protagonist Therapeutics (PTGX) PT Raised to $88 at Truist Securities

Oct 13, 2025 02:04PM Protagonist Therapeutics (PTGX) Said to Be Mentioned Cautiously Regarding M&A

Oct 13, 2025 05:04AM Protagonist Therapeutics (PTGX) PT Raised to $112 at BMO Capital

Oct 10, 2025 01:06PM Protagonist Therapeutics (PTGX) January 95 calls active, share price up 32%

Oct 10, 2025 11:27AM Protagonist Therapeutics stock surges after J&J acquisition talks report

Oct 10, 2025 11:16AM Protagonist Therapeutics (PTGX) halted on volatility

Oct 10, 2025 11:14AM Johnson & Johnson (JNJ) in talks to buy Protagonist Therapeutics (PTGX) - WSJ

Oct 8, 2025 09:08AM BMO Capital on Protagonist Therapeutics (PTGX): 'UEG Icotrokinra Full Data Remains Compelling'

Oct 7, 2025 11:00PM Jefferies says this stock offers favorable setup with further upside potential

Oct 7, 2025 02:50PM Protagonist Therapeutics (PTGX) PT Raised to $74 at Clear Street

Sep 17, 2025 04:35AM Barclays Starts Protagonist Therapeutics (PTGX) at Overweight

Sep 12, 2025 06:02AM Leerink Partners Starts Protagonist Therapeutics (PTGX) at Outperform

Aug 7, 2025 04:18AM Protagonist Therapeutics (PTGX) PT Raised to $69 at Citizens JMP

Aug 6, 2025 06:25PM Protagonist Therapeutics (PTGX) Tops Q2 EPS by 3c

Aug 6, 2025 04:05PM Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 17, 2025 05:19AM Citi Starts Protagonist Therapeutics (PTGX) at Buy

Jun 3, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 3, 2025 05:47AM Protagonist Therapeutics (PTGX) PT Lowered to $62 at Clear Street

Jun 3, 2025 05:16AM BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 2, 2025 10:29AM JPMorgan Reiterates Overweight Rating on Protagonist Therapeutics (PTGX)

View Older Stories